Table 1:
Characteristics of patients with NUT carcinoma
| Characteristic | Overall cohort (n=116) | DNA cohort (n=100) | Exon fusion cohort (n=46) |
|---|---|---|---|
|
| |||
| Age, median (range) — years | 38 (7–76) | 38 (9–76) | 39 (7–73) |
| Sex — no. (%) | |||
| Female | 47 (40.5%) | 40 (40.0%) | 18 (39.1%) |
| Male | 69 (59.5%) | 60 (60.0%) | 28 (60.9%) |
| Race, self-reported — no./total no. (%) | |||
| White | 66/91 (72.5%) | 59/81 (72.8%) | 24/36 (66.7%) |
| Black/African American | 7/91 (7.7%) | 6/81 (7.4%) | 5/36 (13.9%) |
| Asian | 12/91 (13.2%) | 10/81 (12.3%) | 5/36 (13.9%) |
| Other | 6/91 (6.6%) | 6/81 (7.4%) | 2/36 (5.6%) |
| Unknown | 25 | 19 | 10 |
| Ethnicity, self-reported — no./total no. (%) | |||
| Hispanic | 3/83 (3.6%) | 3/75 (4.0%) | 2/33 (6.1%) |
| Not Hispanic | 80/83 (96.4%) | 72/75 (96.0%) | 31/33 (93.9%) |
| Unknown | 33 | 25 | 13 |
| Cigarette Smoking History — no./total no. (%) | |||
| Never | 82/104 (78.8%) | 72/90 (80.0%) | 26/38 (68.4%) |
| Former or Current | 22/104 (21.2%) | 18/90 (20.0%) | 12/38 (31.6%) |
| Pack-years, median (range) | 0 (0–20) | 0 (0–20) | 0 (0–15) |
| Unknown | 12 | 10 | 8 |
| Disease stage | |||
| Metastatic | 67/116 (57.8%) | 56/100 (56.0%) | 26/46 (56.5%) |
| Non-metastatic | 49/116 (42.2%) | 44/100 (44.0%) | 20/46 (43.5%) |
| Site of Primary Disease — no./total no. (%) | |||
| Thoracic | 73/116 (62.9%) | 63/100 (63.0%) | 32/46 (69.6%) |
| Non-thoracic | 43/116 (37.1%) | 37/100 (37.0%) | 14/46 (30.4%) |
| Head and Neck | 38/43 (88.4%) | 33/37 (89.2%) | 12/14 (85.7%) |
| Other | 5/43 (11.6%) | 4/37 (10.8%) | 2/14 (14.3%) |
| NUTM1 - fusion partner — no./total no. (%) | |||
| BRD4 | 55/93 (59.1%) | 47/80 (58.8%) | 22/46 (47.8%) |
| Non-BRD4 | 38/93 (40.9%) | 33/80 (41.3%) | 24/46 (52.2%) |
| BRD3 | 18/36 (50.0%) | 14/31 (45.2%) | 13/24 (54.2%) |
| NSD3 | 16/36 (44.4%) | 16/31 (51.6%) | 9/24 (37.5%) |
| BRD2 | 1/36 (2.8%) | 1/31 (3.2%) | 1/24 (4.2%) |
| ZNF592 | 1/36 (2.8%) | N/A | 1/24 (4.2%) |
| Non-BRD4, Fusion Unknown | 2 | 2 | N/A |
| Unknown | 23 | 20 | N/A |
| PD-L1 Score | |||
| Tumor Proportion Score (%), median (range) | 0 (0–70) | 0 (0–70) | 0 (0–70) |
| Tumor Proportion Score (%) < 1 — no./total no. (%) | 50/60 (83.3%) | 47/55 (85.5%) | 22/28 (78.6%) |
| Tumor Proportion Score (%) ≥ 1 — no./total no. (%) | 10/60 (16.7%) | 8/55 (14.5%) | 6/28 (21.4%) |
| Combined Proportion Score (%), median (range) | 0 (0–30) | 0 (0–30) | 5 (0–20) |
| Combined Proportion Score (%) < 1 — no./total no. (%) | 7/13 (53.8%) | 6/11 (54.5%) | 2/5 (40.0%) |
| Combined Proportion Score (%) ≥ 1 — no./total no. (%) | 6/13 (46.2%) | 5/11 (45.5%) | 3/5 (60.0%) |
| Unknown | 43 | 34 | 13 |
| Tumor Mutation Burden (TMB) | |||
| TMB (mut/Mb), median (range) | 1.0 (0–16) | 1.0 (0–16) | 1.6 (0–16) |
| Unknown | 43 | 29 | 19 |